Shanghai Junshi Biosciences, a Chinese biopharmaceutical company, is targeting to raise $414 million in a Hong Kong initial public offering (IPO).
The company is selling 158.9 million shares at a price range of $2.48 to $2.61.
Shanghai Junshi Biosciences could secure up to $476 million if an over-allotment option is exercised within the first month of trading.
China International Capital Corporation, an investment banking firm, is the sole sponsor for the IPO whereas the joint bookrunner is Swiss peer Credit Suisse.